| Print
Gilead Sciences (GILD)
Common SharesOpen
$103.855
Previous close
$103.17
Trade high
$106.54
Volume
9,458,853
Year high
$119.96
Year low
$62.07
Dividend yield
3%
Market capitalisation
$132.39 bn
P/E ratio
21.67
ISIN
US3755581036
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Share price
Dividends
| Previous | Latest | |
|---|---|---|
| Record date | 14/03/2025 | 13/06/2025 |
| Ex-dividend date | 14/03/2025 | 13/06/2025 |
| Payment date | 28/03/2025 | 27/06/2025 |
| Amount | $0.79 | $0.79 |
Company profile
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.